Quarterly report pursuant to Section 13 or 15(d)

Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Detail)

v2.4.1.9
Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)
3 Months Ended
Mar. 31, 2015
Segment
Dec. 31, 2014
Summary Of Significant Accounting Policies [Line Items]    
Number of Operating segment 1us-gaap_NumberOfOperatingSegments  
Milestones arrangement, categories description Pieris Pharmaceuticals, Inc. aggregates milestones into three categories (i) research milestones, (ii) development milestones and (iii) commercial milestones.  
Effective tax rate 0.00%us-gaap_EffectiveIncomeTaxRateContinuingOperations  
Fair Value, Inputs, Level 1 [Member]    
Summary Of Significant Accounting Policies [Line Items]    
Cash and Cash Equivalents, Fair Value 471,011us-gaap_CashAndCashEquivalentsFairValueDisclosure
/ us-gaap_FairValueByFairValueHierarchyLevelAxis
= us-gaap_FairValueInputsLevel1Member
$ 4,800,573us-gaap_CashAndCashEquivalentsFairValueDisclosure
/ us-gaap_FairValueByFairValueHierarchyLevelAxis
= us-gaap_FairValueInputsLevel1Member